Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma

Background Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy showed remarkable efficacy in patients with relapsed or refractory multiple myeloma (RRMM). This phase 1 dose-escalation and expansion study developed C-CAR088, a novel second-generation humanized anti-...

Full description

Bibliographic Details
Main Authors: Yan Zhang, Lu Zhang, Xian Zhang, Xin Yao, Tingyu Wang, Dan Zhu, Liping Lan, Peihua Lu, Yihong Yao, Lugui Qiu, Xiaoyan Qu, Gang An, Weiwei Sui, Junfang Yang, Jiaqi Huang, Shigui Zhu, Chengxiao Zheng, Kevin Zhu, Yutian Wei, Xiaoteng Lv, Daobin Zhou, Jianyong Li
Format: Article
Language:English
Published: BMJ Publishing Group 2022-09-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/9/e005145.full

Internet

https://jitc.bmj.com/content/10/9/e005145.full

Similar Items